



ASX Release

Settlement actions completed with Prime and Manukan; Crescendas debt paid

Sydney, 27 September 2017

Memphasys (**ASX: MEM**) reports that the following settlement actions have been completed with PRIME Biologics Private Limited (“**Prime**”) and Pulau Manukan Ventures Labuan Ltd (“**Manukan**”) in accordance with the Settlement Agreement signed between the parties on 24 July 2017. ASX announcements related to the Settlement Agreement were made on 27 and 28 July 2017:

- Manukan now has full rights and ownership over the Preference B Shares in Prime formerly owned by Memphasys.
- Memphasys is clear of the SG\$4.8m debt.

In addition, the \$250,000 debt plus interest has been fully repaid to Crescendas Projects Pte Ltd. Details of the loan to the Company were outlined in an ASX announcement on 2 March 2017.

For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Memphasys Limited
30-32 Richmond Road
Homebush West NSW 2140

Postal Address
P.O. Box 2202
Homebush West NSW 2140

Contact Details
P +612 8415 7300
F +612 8415 7399

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556